Search results: (10000)
News Intestinal Infection of Multi-Resistant NDM-Producing K. pneumoniae in a Patient with NK/T Lymphoma – Case Study
The incidence of NDM-producing Klebsiella pneumoniae is increasing worldwide. NDM beta-lactamase is a significant cause of multidrug resistance in enterobacteria to various antibiotics, including carbapenems. Currently, the most suitable approach for the treatment of intestinal infections caused by NDM-producing K. pneumoniae is considered to be the combination of ceftazidime/avibactam with aztreonam. The following case study also illustrates its use in more complicated cases.
News Advances in the Treatment of Myasthenia Gravis on the Horizon
The research of new drugs for the generalized form of myasthenia gravis has made significant progress in recent years. How is the new specific therapy performing? And are we heading towards a radical change in treatment strategy?
News Teriflunomide "under the microscope" or what it's like to live with MS in the North
The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the quality of life of patients with multiple sclerosis (MS) according to data from real clinical practice in the Nordic countries? What is adherence to this therapy like? And what are its health-economic consequences? We briefly summarize the answers to these questions.
News Tailored Treatment. Who is Teriflunomide Suitable For?
The authors of the recently published study cited below not only focused on the safety and efficacy of teriflunomide in real-world clinical practice but also on the risk factors for its insufficient effectiveness. Who is teriflunomide most suitable for, and when should alternatives be considered?
News Cognitive changes in MS – what can teriflunomide do?
In Phase III clinical trials, teriflunomide demonstrated its ability to slow down brain tissue atrophy in patients with relapsing-remitting multiple sclerosis (RRMS). What impact did the treatment have on the cognitive state of these patients?
News Dust mite allergy is a significant risk factor (not only) for the development of asthma
Dust mite allergy is the most common cause of year-round allergic rhinitis in our country. Its prevalence is increasing every year, but non-specific manifestations also cause its underdiagnosis. Early initiation of treatment is crucial to prevent the development of complications.
News DPP4 Inhibitors in Chronic Kidney Disease and Their Potential to Protect Against Diabetic Nephropathy
Preclinical and clinical observations suggest that dipeptidyl peptidase 4 (DPP4) inhibitors might offer additional benefits to patients apart from effective and safe glycemic control.
News Irritable Bowel Syndrome and Non-specific Inflammatory Bowel Diseases Are Not Evolutionarily Related Diseases
The authors of the presented work attempted to compare the geographical distribution of irritable bowel syndrome and non-specific inflammatory bowel diseases and other factors related to these two diseases to reveal their potential evolutionary connection.
News Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
A recent survey among German-speaking physicians evaluated the use of non-opioid analgesics in perioperative care in children under 14 years. It focused on the use of metamizole and the monitoring of possible agranulocytosis associated with this drug.
News Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in which the authors thoroughly examined current knowledge on the epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction of the left ventricle (HFpEF). Recent studies in this heterogeneous disease suggest the importance of carefully determining the HFpEF phenotype in a given patient based on pathophysiology, which enables better individualization of treatment. The authors also reflect on the success of gliflozins in treating HFpEF and how HFpEF pharmacotherapy can be further improved.
News Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for chronic lymphocytic leukemia (CLL) and are now an integral part of treatment regimens, including the 1st line. Individual therapeutic approaches and strategies based on them have their advantages and disadvantages as well as their target patient group, but the concept of time-limited treatment is increasingly gaining ground. Therapy today is significantly individualized, and its optimal choice is based on the assessment of various circumstances on the patient’s part and their disease.
News EAHAD 2024: Fresh results of paradigm5 and 6 studies confirm safety and efficacy of N9-GP
Nonacog beta pegol (N9-GP) is a recombinant factor IX with an extended half-life. Its properties allow for the maintenance of a satisfactorily high level of FIX with intravenous application once a week. At the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held in early February 2024 in Frankfurt, new findings on this treatment were presented during a satellite symposium by Novo Nordisk.
News ACC 2023 Expert Consensus: How to Optimize Diagnosis and Treatment of Heart Failure with Preserved EF LK
Heart failure (HF) remains a significant cause of morbidity and mortality, with the incidence and prevalence of HF with preserved left ventricular ejection fraction (HFpEF) rising. The following document focuses on individuals with HFpEF and supports the principles of evidence-based diagnosis and treatment of HF from 2022. It emphasizes the need for individualized care and multidisciplinary cooperation.
News How Does Artificial Intelligence Help in Drug Development?
In recent years, technologies leveraging artificial intelligence have transitioned from potentially interesting novelties to real clinical development programs. What can artificial intelligence offer the development of new drugs?
News Improvement in social functioning of patients with schizophrenia during treatment with lurasidone
A beneficial impact on social functioning is an important outcome of schizophrenia treatment. A recently published Japanese study is the first to demonstrate the efficacy of lurasidone compared to placebo on the social functioning of patients with schizophrenia. The results are comparable to other atypical antipsychotics.